PHARMACOKINETIC STUDY ON CEFUZONAM IN PATIENTS WITH REGULAR HEMODIALYSIS TREATMENT
1990 Volume 38 Issue 6 Pages 570-575
Details
1990 Volume 38 Issue 6 Pages 570-575
A pharmacokinetic study of cefuzonam (CZON), one of the new third-generation cephems, was performed in four hemodialyzed patients on days with and without regular hemodialysis (HD) treatment (cross-over method). All subjects had normal liver function.
CZON (1.0g) was administered by a single i. v. injection for 5 min, and blood samples were collected at selected time intervals. Serum concentrations of the drug were measured by highperformance liquid chromatography.
The pharmacokinetic parameters of CZON were calculated from the average serum concentrations, according to both one-compartment model (dialysis session time, 1-6 h afterinjection) and two-compartment model (whole time, 1-24 h after injection). Overall T1/2 was 2.419 ±0.619 h on the HD day, and 2.794± 0.316 h on the off-HD day. The T1/2 of the dialysis session time was 1.916±0.434 on the HD day and 2.145±0.793 on the off-HD day. The T1/2 in hemodialyzed patients was about 2 times longer than normal subjects. For T1/2, no significant difference was found between the on-HD and off-HD day. Similarly, For both AUC and Clt, there was no significant difference.
Assuming that 1.0g of CZON was given by i. v. injection once a day for 1 week to hemodialyzed patients, we calculated the changes in serum concentration. On such a schedule CZON was revealed to be non-cumulative in patients with HD treatment thrice a week.
We conclude that the T1/2 of CZON in hemodialyzed patients is longer than in normal subjects but that there is little dialysis effect on the serum concentration of CZON. We suspect, however, that extra-renal or extra-dialysis elimination is increased.
